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HL-60 cells are very sensitive to the cytotoxic action of ether lipids. Several hypotheses have been proposed to explain this cytotoxicity. We 
investigated the huluence of the alkylphosphoiipid ET-i8-OCHl on the activity of protein kinase C. HL-60 cel!s were incubated with ET-18-OCH; 
at a concentration of 20 pg/rnl for 4 h. After the incubation the membrane fraction of the HL-60 cells was isolated and the activity of protein kinase 
C was determined while it was still associated with the membrane, using the synthetic peptide substrate [SeP’]-protein kinase C (19-S 1) as a protein 
kinase C specific substrate. The activity of the membrane-bound protein kinasc C was increased in HL-60 cells treated with ET-lg-OCHS compared 
to untreated HL-60 cells. The increase in protein kinase C activity was not a consequence of translocation and appeared to be additive to the effect 
of the phorbol ester 12myristate 13-acetate. In contrast, solubilized protein kinase C from HL-60 cells could be inhibited or stimulated in vitro 
by ET-18-OCH,, dependent on the mode of addition of ET-18OCHs and phospholipids. 
Alkyllysophospholipid; ML-60 cell; Protein kinase C 
1. INTRODLJCTION 
The ether lipid ET-1%OCXI, is a synthetic analog of 
Slysophosphatidylcholine and acts as an strong antitu- 
mor agent [1,2]. The mechanisms by which ET-18- 
0CH3 exerts its selective antineoplastic activity is a 
point of great discussion. Various mechanisms have 
been proposed to be of importance in the cytotoxic 
action of ether lipids such as disturbance of the phos- 
pholipid metabolism of the plasma membrane [3,4], in- 
fluence on membrane fluidity [5,6] and permeabilization 
of neoplastic ell membranes [7,8]. Frequently the inhi- 
bitory effect of ether lipids on the activity of PK-C have 
been mentioned as a possible explanation for the an- 
tineoplastic action of ether lipids [9-l l]. These studies 
however, were performed in vitro with (partially) 
purified PK-C and artificial membrane structuees com- 
posed of phosphatidylserine and diolein. HL-60 cells 
are highly sensitive to the cytotoxis action of ET-18- 
0CH3. To investigate the effect of ET-1%OCH, on PK- 
C in its native environment, we isolated the plasma 
membrane of HL-60 cells, before and after incubation 
with ET-18- OCH,. The activity of PK-C was de- 
termined in the plasma membrane fraction when it was 
still in its native phospholipid environment [12]. The 
data presented in this paper show that incorpolration of 
ET-l g-OCH, in the plasma membrane stimulates PM-C 
activity and that an inhibitory effect of ET-18-OCH, on 
PK-C activity is only achieved under conditions where 
the ether I,pid is present in micelles, 
2. NIATERIALS AND NIETHODS 
2.1. Materials 
All materials used for cel1 culture were obtained from Gibco (Grand 
Island, NY). ET-I&0CH3, phosphatidylserine, diolein, Ieupeptin, 
aprotinin and dithiothreitol were from SigmaChemical Co. (St. Louis, 
MO). DE-52 (DEAE-cellulose) and P81 filter paper were purchased 
from Whatman. [y-“*P]ATP (3000 Ci/mmol) was supplied by New 
England Nuclear (Boston, MA). Calpain inhibitor-l was from Boeh- 
ringer (Mannheim, Germany) and protein kinase C synthetic peptide 
substrate [Ser2’]-protein kinase C (19-31) was supplied by Bissendorf 
Biochem. (Hannover, Germany). 
2.2. Cells 
HL-60 cells obtained from the American Type Cultuee Collection 
(Rockville, MD) were grown in suspension i  RPM1 1640 medium, 
containing 10% FCS (heat-inactivated), 2 mM glutamine, penicillin 
(100 units/ml) and streptomycin (100 @/ml) at 37OC and 5% C02. 
HL-60 cells were grown in log-phase and harvested routinely. Phorbol 
12.myristate 13-acetate (PMA) was dissolved in DMSO and added to 
the ceils at a final concentration of 200 nM (and 0.01% DMSO), 20 
mir before harvesting. ET-18.OCH5 wasdissolved in RPM1 1640 with 
20% AB serum and filtered through a 22 pm filter and stored at 
-20°C. ET-1X-OCH1 at a final concentration of 20 /@/ml was added 
to the cell suspension 4 h before harvesting. 
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2.3. Assay of protein ltinase C activity 
Membrane associated PK-C: HL-60 cells (6.106/assay) were washed 
twice with phosphate buffered saline (PBS) and lysed in a 50 mM 
Tris-WC1 buffer, pH 7.5, containing I mM NaHCOJ, 5 mM MgCI,, 
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1 mM phcnylmethylsulphonylfluoride (PMSF), I PM calpain inhibi- 
tor-I and 50 @ml leupeptin. Cells were disrupted by successively 2 
min agitation on a vortex mixer, 30 strokes in a potter Elvehjem and 
5 s sonication in a Branson soaifier. All procedures were carried out 
at 4°C. The cell lysate was centrifuged at 800 x g for IO min to remove 
nuclei and cell debri and subsequently centrifuged at 48 000 x g for 
30 min at 4°C. The 48 000 x g pellet fraction was resuspended in lysis 
buffer and again centrifuged at 48 000 x 8 for 30 min at 4°C. The 
resulting cell pellet was resuspended in a small volume of assay buffer 
(10,~1/6~10~ cells) containing 30 mM HEPES-KOH (pH 7.5)and 5 mM 
magnesium acetate. The assay mixture, with a final volume of 40 ,uI, 
consisted of assay buffer, 25 PM [Se?‘]-protein kinase C( 19-30) and 
10 ~1 membrane fraction. The reaction was started with 20 ,uM 3zP- 
APP (I. 1 x IO6 cpm) and carried out at 30°C for 3 min. The reaction 
was stopped by spotting aliquots of reaction mixture in duplicate on 
HxPC& pretreated P81 filter papers. Excess ofradioactivity was washed 
from the filters in a 75 mM I&POP solution (5 times refreshed). The 
remaining radioactivity was determined with Optiftuor and counted 
with a liquid scintillation counter. PK-C activity is expressed in pmol 
ATP/miniiO” ceiis. Partially purified PK-C: 10’ HL-60 cells \uere 
washed twice with PBS. Cells were lysed in extraction containing: 20 
mM Tris-I-ICI, pH 7.5, IO mM EGTA, 2 mM EDTA, 0.25 M sucrose, 
1 mM PMSF, lO&ml leupeptin, 200 nM aprotinin and 1 ,uM calpain 
inhibitor-l. Cells were disrupted by ultrasonication, (2 x S s with 1 min 
interval) at 4°C with a Branson sonifier. The extracts were centrifuged 
for 30 min at 48 000 x g at 4°C. The supernatant was collected and 
PK-C was partially on DES2 gel [l3]. The membrane fraction was 
subsequently resuspended in extraction buffer to which 0.5% Triton 
X-100 was added, incubated for 30 min on ice and centrifuged for 30 
min 48 000 x g. The supernatant with the solubilized PK-C was collec- 
ted and subjected to DE-52 [ 133. PK-C activity was determined as 
described by Kikkawa et al. [13] with some modifications. Briefly, the 
reaction mixture with a final volume of SO ~1 contained: 30 mM 
HEPES-KOH, pN 7.5,s mM magnesiumacetate, 0.5pg phosphatidyl- 
serine, 0.1 ~10 diolcin and 0.5 mM CaCI,. Negative controls were 
performed with OS mM EGTA instead of CaCI,, phosphatidylserine 
and diolein. The reaction was started with 1OyM [‘*P]ATP (2.2 x IO’ 
cpm) and performed at 30°C for 3 min. The incorporated radioactivity 
was determined as described above. 
0 10 20 30 
incubation time bin) 
Fig. I. Time course of PMA incubation. HL-60 cells were incubated 
with PMA for 10, 20 or 30 min. PK-C activity in the membrane 
fraction was determinsd as described in section 2. PMA dissolvent 
DMSO, in a final concentration of 0.01%. had no influence on the 
PK-C activity. PK-C activity is expressed in pmol/min/106 cells. Values 
represent mean of 3 independent experiments SD. 
I-IL-60 cells measured with (partially) purified PK-C 
[17] showing that our model is very useful to investigate 
the activity of PK-C in its native environxnent. The 
action of ET-l&OCH, on PK-C in I-IL-60 cells was 
investigated at subtoxic concentrations of ET-1 g- 
QCI-I,, 2O,@nl for 4 h at 37°C [18]. After 4 h incuba- 
tion the viability of the cells was approx. 80% as de- 
termined with Trypan blue dye exclusion. 
Quite unexpectedly, we found a 3-fold increase in 
PK-C activity in the membranes of ET-18-OCI$ treat- 
L 
3. RESIJETS AND DISCIJSSION 
In search for answers to the mechanisms by which 
ALP exerts its antineoplastic action, many investigators 
focussed on the inhibitory a&ion of ET-18-OCI-I, on 
PK.-C, an enzyme that plays a central role in cellular 
signal transduction and also serves as an intracellular 
receptor for tumor-promoting phorbol esters [14]. Puri- 
fied PK-C, isolated from I-IL-60 cells, was inhibited by 
ET-18-OCI-13 with a & of 9-l!I@I [13,15,16]. The inhi- 
bition appeared to be competitive with respect o phosp- 
hatidylserine. 
In our laboratory we were interested in the action of 
ET- 18-OCI& on PK-C under more physiological condi- 
tions, e.g. when PK-C was still associated with the 
plasma membrane. In order to investigate this we de- 
veloped a new model for testing PK-C activity as a 
modification of the model of Chakravarthy et al. [12]. 
HE-60 cells were treated 10, 20 and 30 min with the 
phorbol ester PMA. Afterwards the membrane fraction 
was isolated and the PK-C activity was measured as 
described in section 2. An optimum in PK-C activity 
was achieved after 20 min of PMA incubation (Fig. I). 
These results are in accordance to what was found in 
3 
T 
t-0 additions PMA ET-18-0~3-4, ET-if-OCH, 
PMA 
Fig. 2. PK-C activity in the membrane fraction of control HL-60 cells, 
cells incubated with 200 nM PMA for 20 min, 20,~uglml ET-l8-OCH, 
for 4 h, or with both ET-l8-OCH, (20pg/ml for 4 h and 200 nM PMA 
for 20 min). Hatched bars: PK-C activity in the membrane fraction 
determined as described in section 2. Open bars: PK-C activity in the 
membrane fraction measured in the presence of 20 nM staurosporin. 
Condensed hatched bars: endogenous phosphorylation, phosphoryla- 
tion without synthetic peptide as substrate in the PK-C assay mixture. 
PK-C activity is expressed in pmol/min/106 cells. Values represent 
mean of 6 independent experiments SD. 
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Table I 
Distribution of Protein kinase C activity in HL-60 control cells of 
PMA/ET-I S-OCH, treated cells 
Fraction PMA ET- I S-OCH, PK-C activity 
(nmol/min/mg 
protein) 
Cytosol - 2.1 f 0.5 
+ 0.5 + 0.2 
c 2.0 + 0.5 
Membrane 0.7 + 0.3 
+ 1.8 -+ 0.5 
+ 0.9 t 0.2 
I-IL-60 cells were incubated with 2Opg ET-IS-QCH3 for 4 h or 200 nM 
PMA for 20 min. PK-C was partially purified and assayed as described 
in section 2. The results are the mean of at lcast 3 independent expe- 
riments +SD. 
ed cells compared to untreated HL-60 cells (Fig. 2). 
The phosphorylation reaction could be inhibited to a 
level of 0.1350.01 pmol ATP/min/lO” cells in the pre- 
sence of 20 n&I staurosporin, an inhibitor of PK.-C [19] 
(Fig. 2). Endogenous phosphorylation, without the syn- 
thetic peptide in the assay mixture, resulted in a similar 
level of phosphorylation (Fig. 2). The question re- 
mained whether the increase in PK-C activity was the 
result of a PK-C redistribution from the cytosolic frac- 
tion to the membrane fraction (similar to the PMA 
ET- 18-OCH, Fglml 
Fig. 3. Effect of ET-IS-OCHX on partially purified PK-C. ET-IS- 
0CH3 was added tc !be reaction mixture under 3 different conditions 
as described in section 3, respectively methods (i), (ii) and (iii). (M) 
ET-IS-OCPI3 dissolved in ethanol as described in method(i). Ethanol, 
with a final concentration of 1% had no influence on the PK-C activ- 
ity. (A) ET-18-OCHA added to the reaction mixture as mixed liposo- 
mes (with phosphatidylserine and diolein), as described in method (ii). 
((8)) ET-IS-0CH3 added to the reaction mixture as separate liposomes, 
as described in method (iii). k’,,,,, represents the IX-Cactivity measured 
under standard conditions (without ET-18-OCHJ in the assay mix- 
ture) as described in section 2. 100% I’,,,% activity of PK-C is 2.lk0.5 
nmol/min/mg protein. Values represent mean of 3 independent experi- 
ments with SD always under 10%. 
effect) or whether we are dealing with another pheno- 
menon mduced by ET-I &OCH,. Translocation of PK- 
C was investigated with two methods. First we incu- 
bated HE-60 cells with both ET-18-OCHJ and PMA 
(the latter was added the last 20 min of ET-l&-0CH3 
treatment). As shown in Fig. 2 an additive efect of ET- 
18-0CH3 and PMA on PK-C in the membrane fraction 
was seen. Obviously, the PMA was still capable of pro- 
moting a redistribution of cytosolic PK.-C to the mem- 
brane fraction after ALP treatment. Secondly, we per- 
formed a partial purification of PK-C in both the cyto- 
solic and membrane fraction of cells treated with PMA 
or ET-l&OCH,. As shown in Table I, a 75% deerease 
was observed in the cytosol fraction of PMA treated 
cells whereas the PK-C activity in the cytosol fraction 
of ET-l&OCH, treated cells remained the same. The 
PMA treatment resulted in an increase in PK-C activity 
:n * the memb:ane f:ac:ion. The PK-C activity in the 
membrane fraction of HL-60 sells treated with ET-I& 
0CH3 was similar to that in control HL-60 cells due to 
the solubilization procedure with 0.5% Triton X-100. 
These observations indicate that ET-l 8-OCH, does not 
promote a redistribution of PK-C from the cytosol to 
the membrane fraction. Incubation of HL-60 cells with 
cycloheximide (30 @g/ml), an inhibitor of protein syn- 
thesis, together with ET-I 8-OCH3 did not influence the 
increase in PK-C activity, concluding that de novo syn- 
thesis of PK-C is not responsible for the increase in 
activity. 
To unravel this striking effect of ET-I$-OCH, on 
PK-C when measured in this model and the complete 
contradictory observations reported by other investiga- 
tors, we also studied the effect of ET-18-0CH3 in the 
conventional conditions as described by Kikkawa et al. 
[ 131. Cytosolic PK-C from HL-60 cells was isolated and 
partially purified with DE-52 chromatography. ET-18- 
OCH, was added to the assay mixture under three con- 
ditions. (i) ET-I&0CH3 was dissolved in 100% ethanol, 
subsequently diluted in assay buffer to the desired con- 
centration with a final concentration of 1% ethanol in 
the assay. PS and diolein were added as a liposome 
structure as described by Kikkawa et al. [ 131. (ii) ET-I 8- 
0CH3 was dissolved in chloroform, each concentration 
of ET-18-0CH3 was separately evaporated under a 
stream of nitrogen together with PS and diolein, and the 
mixture was resuspended in assay buffer by ultraso- 
nication. By this procedure mixed liposomes are formed 
containing PS, diolein and an increasing amount of ET- 
18-0CH3. (iii) ALP was dissolved in chloroform and 
each concentration was separately evaporated under Nz 
and resuspended in assay buffer by ultrasonication. Li- 
posomes of PS and diolein are made as described under 
(i) and added to the assay mixture separately from the 
ET- 18-0CH3 liposomes. 
The results of this comparative study are shown in 
Fig. 3. PK-C activity is inhibited by ET-18-OCH, when 
added under the conditions as described by method (i). 
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This result is in accordance with those presented by 
Helmann et al. [S] and §hoji et al. [ 1 I]. The inhibition 
was described as competitively with respect to PS and 
to the activation by diacylglyerol or TPA. The lack of 
inhibitory action of ET-18-0CH3 on PK-C activity 
when added as separate liposomes (method (iii)) is re- 
markable and might explain the findings of Van Blit- 
terswijk et al. [20] who found no inhibition of PK-C by 
the ether lipid when added as separate liposomes. Even 
more striking is the effect of ET-I8-0CH3 when incor- 
porated in the PS and diolein liposomes (method (ii)). 
The action of t.he ether lipid resembles that of lyso- 
phosphatidylsholine as described by Oishi et al. [Zl]. 
Linking the results obtained in the different experi- 
ments we can conclude that ET-18-0CPE3 is an activator 
of PK-C when incorporated in the membrane of HE-tj0 
cells or in membrane structures as shown in Fig. 3. 
Inhibition of PK-C by ET-18-0CH3 can only be 
achieved under conditions where the ether lipid is pre- 
sent in mi.sell.es. The physiological consequences of this 
finding are unclear. In contrast to the L:eneral assump- 
tion, ET-18-0CH3 obviously does not act as an inhibi- 
tor of PK-G in HL-60 cells when incorporated in the 
plasma membrane. In this respect it is of interest that 
naturally occurring ether-diglycerides are recently de- 
scribed as activators of PK-C 1221. Further investiga- 
tions on the mechanisms of action of ET-18-0CH3 on 
PK-C activity, and additionally the effects of ether li- 
pids on PK-C from resistant cell lines are now ongoing 
in order to fnrther elucidate or reject a possible role of 
PK-C in the antineoplastic action of ET-18-OCH3. 
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